Piper Jaffray Initiates Coverage on ABIOMED (ABMD) with a Buy; Stock Appears Oversold
Tweet Send to a Friend
Piper Jaffray & Co initiates coverage on ABIOMED (Nasdaq: ABMD) with a Buy. Price target $8.
Piper analyst says, "Abiomed's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Piper analyst says, "Abiomed's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
